From the Departments of Biology and
¶ Pediatrics, Carmel Medical Center and the Faculty of
Medicine, Technion-Israel Institute of Technology, Haifa, 32000, Israel
and the § University of Hannover, Department of Inorganic
Chemistry, Callinstr. 9, 30167 Hannover, Germany
Received for publication, June 21, 2000, and in revised form, October 25, 2000
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The standard treatment of human visceral
leishmaniasis involves the use of pentavalent antimony
(SbV). Its mechanism of action is unknown because of
the limited information available about intracellular antimony
metabolism and about the genes that regulate these processes. Herein,
flow injection-inductively coupled plasma mass spectrometry (ICP-MS),
flow injection hydride generation ICP-MS, and ion chromatography ICP-MS
were used to measure antimony accumulation and intracellular metabolism
in the human protozoan parasite Leishmania donovani.
Amastigotes (the intracellular form) and promastigotes (the
extracellular form) accumulate SbV and SbIII
via separate transport systems. Stage-specific intracellular SbV reducing activity was apparent in amastigotes,
which reduced the negligibly toxic SbV to highly toxic
SbIII. This amastigote-specific reducing activity was
deficient in the Pentostam-resistant mutant L. donovani
Ld1S.20. These data indicate that parasite susceptibility to
SbV correlates with its level of SbV reducing
activity. Also, in promastigotes of both wild-type L. donovani and the Pentostam-resistant mutant L. donovani Ld1S.20, SbV inhibited the toxicity of
SbIII but not of AsIII. Both SbV
and SbIII were toxic to wild-type amastigotes. However, as
observed in promastigotes, in mutant amastigotes SbV
inhibits SbIII but not AsIII activity. Anion
exchange chromatography showed that intracellular antimony metabolism
occurred in both promastigotes and amastigotes. These data demonstrate
that the interaction between the two antimony oxidation states occurs
intracellularly, within the parasite. The results also indicate that
SbV anti-leishmanial activity is dependent on its reduction
to SbIII. The mechanism of this novel intracellular
SbV reduction has yet to be identified, and it may or may
not be enzymatic. This is the first description of intracellular
SbV reducing activity in Leishmania as well as
in any prokaryotic or eukaryotic cell.
Leishmania donovani is the major causative agent of
visceral leishmaniasis. In nature, the parasite exists either as an
extracellular promastigote found in the alimentary tract of sandflies
or as an obligatory intracellular amastigote found in phagolysosomes of
mammalian macrophages(1-3). During the last several years, a number of
laboratories have utilized axenic culture of L. donovani amastigotes for the direct evaluation of cell biological and
biochemical processes in the amastigote, devoid of the host macrophage
(4-7,8,9,10). This technique has also been used to investigate the
mechanism of drug action and resistance as well as for screening of
potential new drugs(11-13). The treatment of choice of human visceral
leishmaniasis is the administration of pentavalent antimony
(SbV)-containing drugs such as sodium stibogluconate
(Pentostam, Wellcome, Beckenham, UK) or meglumine antimoniate
(Glucantime, Rhone-Poulenc, Paris, France). Despite extensive use of
these compounds over the last decades, the mechanism of action remains unclear.
It has been hypothesized that SbV is not toxic to
Leishmania, but rather that it is enzymatically reduced,
probably by the host macrophage, to SbIII, the form of
antimony that is highly Leishmania-toxic (14-18). In
contrast, it has been shown that SbV is directly toxic to
axenic amastigotes (12, 13, 19), thus negating the necessity of the
macrophage for SbV reduction. Furthermore, these data imply
that either the parasite reduces SbV to SbIII
intracellularly, and thus SbIII is directly toxic to
amastigotes, or that both oxidation states of antimony are active
against Leishmania amastigotes. The modes of action of the
two oxidation states of antimony (SbIII and
SbV) on Leishmania are, as yet, not fully understood.
Several groups have shown obligatory cross-resistance between
SbV, SbIII, and arsenite (AsIII) in
Leishmania tarentolae, Leishmania major,
Leishmania mexicana, L. donovani and Leishmania
infantum (11, 20-22). In contrast, it has been suggested that, at
least in L. donovani, such cross-resistance does not
necessarily occur (12). Furthermore, it has been demonstrated that,
when bound to organic compounds, structural similarities exist between
SbIII and SbV (23). For example, the trivalent
antimony compound potassium antimonyl tartrate has a structure
resembling that of the pentavalent antimony compound sodium
stibogluconate. Thus it is conceivable that SbV and
SbIII act on a common parasite target molecule. It is also
possible that, when given together, these compounds might act
additively or synergistically, or might inhibit one another. It is also
possible that at least part of the anti-leishmanial activity of
AsIII may not be mediated by a mechanism similar to that of
antimony despite the fact that cross-resistance in other
Leishmania species has been observed (11,20-22).
To understand the relationships between these compounds and their
activity against L. donovani, antimony accumulation and its
subsequent intracellular metabolism were investigated using novel
antimony speciation methods.
Materials
Sodium stibogluconate (powder) was a gift from The Wellcome
Trust (Beckenham, UK). Potassium antimonyl tartrate was obtained from
Sigma Chemical Co. (St. Louis, MO.). [3H]Thymidine was
obtained from PerkinElmer Life Sciences. Medium 199 and fetal calf
serum were obtained from Biological Industries, Inc. (Bet Haemeek,
Israel). Materials for antimony determinations were as follows: sodium
tetrahydridoborate (puriss. p.a. for determination of hydride formers)
and potassium fluoride (MicroSelect; >99.5% purity) were obtained
from Fluka, Inc. (Seelze, Germany), potassium iodide (puriss, p.a.;
>99% purity) was obtained from Sigma-Aldrich, Inc. (Deisenhofen,
Germany). All other chemicals were of analytical grade.
Parasites
A cloned line of L.donovani 1SR (5,24) and the
Pentostam-resistant mutant L. donovani Ld1S.20 (13) were used.
Culture
Promastigotes were grown in medium 199 at 26 °C and
supplemented with 10% fetal calf serum. In vitro culture of
amastigotes was performed as described by Saar et al. (5).
Transformation of amastigotes to promastigotes was performed by
centrifugation of amastigotes (1,200 × g, at room
temperature for 10 min), suspension in promastigote medium, and
incubation at 26 °C. Under these conditions, amastigotes
differentiate to promastigotes within 48 h (5).
Dose Response Analyses
Parasite viability was measured using a radiolabeled thymidine
incorporation assay as follows: mid-log phase cells (~5 × 105 cells/ml) were added in duplicate to 24-well
flat-bottomed microtiter plates (2-ml final volume). Drugs were
serially added to the cells (either promastigotes or amastigotes), and
cells were then incubated for 48 h at either 26 °C
(promastigotes) or 37 °C in 5% CO2 (amastigotes). Subsequently, 10 µl of [3H]thymidine (0.1 mCi/ml) were
added to each well and incubated for another 3 h (promastigotes)
or 24 h (amastigotes). 1-ml aliquots from each well were
centrifuged (1,200 × g at room temperature for 10 min)
and added to 5 ml of ice-cold trichloroacetic acid, vortexed, and
incubated on ice for about 20 min. Samples were then filtered through a
glass microfiber filter (GF/C, Whatman International Ltd., Springfield
Mill, UK) and washed once with 10 ml of cold trichloroacetic acid
followed by 10 ml of 95% ethanol. Radioactivity was measured using
Determination of Intracellular Antimony
Cell Preparation--
L. donovani promastigotes and
amastigotes were incubated for 3, 6, or 12 h with potassium
antimonyl tartrate (34 µg of SbIII/ml, 0.28 mM SbIII), sodium stibogluconate (1 mg of
SbV/ml, 8.2 mM SbV), or both.
Subsequently, cells were washed twice with ice-cold phosphate-buffered
saline and then extracted with concentrated nitric acid.
Determination of Total Antimony--
The content of antimony in
each sample was measured using flow injection-inductively coupled
plasma-mass spectrometry
(FI-ICP-MS)1 at
m/z 121 using water as solvent stream (flow rate was 1.5 ml/min, n = 5) under clean room conditions (class
1000). Each sample contained 100-µl aliquots of cell extract, which
were diluted 1:100 with water (25, 26). For each measurement, aliquots
of 10 µl were injected with five repetitions.
Determination of SbIII and
SbV--
Intracellular SbIII and
SbV were measured using flow injection-hydride
generation-inductively coupled plasma-mass spectrometry (FI-HG-ICP-MS),
which has recently been developed (27). Briefly, SbIII was
reduced to antimony hydride (SbH3) using 0.2% sodium
tetrahydridoborate in de-ionized water and was directly quantified
using mass spectrometry at m/z 121. To avoid
SbV interference with the antimony hydride measurements,
the SbV reduction was suppressed by the addition of 100 mg/liter of fluoride (as KF) to the solvent stream. Subsequently,
SbV was reduced to antimony hydride in 2 steps;
pre-reduction using 1.2% KI followed by reduction with 0.2% sodium
tetrahydridoborate, both in de-ionized water as solvent stream. The
SbV content in each sample was calculated as the difference
between the absorbance determined after the second reduction
(SbIII + SbV) and first reduction
(SbIII). Nonreducible organic antimony is not detected by
this method. For each measurement, aliquots of 100 µl were injected
with five repetitions.
Anion Exchange Chromatography of Intracellular
Antimony--
Chromatographic separation of intracellular antimony was
done as described by Ulrich et al. (28). Briefly,
cell extracts were diluted 1:100 with distilled water, and 100-µl
aliquots from each preparation were injected into a laboratory-packed
PRP-X100 HPLC column. SbV and SbIII were eluted
from the column using 15 mM nitric acid and were directly
injected to ICP-MS (m/z 121) for antimony
absorbance. Each sample was filtered and degassed prior to chromatography.
Antimony accumulation in promastigotes and amastigotes of both the
wild-type and the mutant L. donovani Ld1S.20 was determined using two different methods. First, total intracellular antimony content was measured with FI-ICP-MS (25, 26), and the results are
summarized under "Total [Sb]i" in Tables
1 and 2. The second method used to determine the content of antimony hydride
(SbH3) was FI-HG-ICP-MS (27, 28). In this method,
SbV and SbIII in cell extracts were separately
reduced to SbH3, which then flowed through the plasma to
the mass spectrometer, where its concentration was subsequently
determined (Tables 1 and 2, [SbV]i and
[SbIII]i). This method enables the
determination of the intracellular content of each of the antimony
oxidation states.
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-scintillation counting. Results were expressed as percentage viability.
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
Accumulation of antimony by L. donovani promastigotes
Accumulation of antimony by L. donovani amastigotes
As shown in Table 1 (Total [Sb]i), in WT promastigotes, SbIII or SbV each accumulated intracellularly after a 12-h incubation. Furthermore, when WT promastigotes were simultaneously incubated with both SbV and SbIII, the total [Sb] measured intracellularly approximated the sum of the intracellular concentrations of the two antimony oxidation states when incubations were with SbV or SbIII alone. The same was true with promastigotes of the mutant L. donovani Ld1S.20.
With a similar set of experiments using WT and mutant amastigotes, the data in Table 2 (Total [Sb]i) show that both SbIII and SbV were accumulated intracellularly. SbV accumulation was concentration-dependent, suggesting that its transport may be mediated by a permease. When compared with promastigotes, the transport of SbV into WT amastigotes is 6.7- and 4.9-fold greater, when incubation was with SbV alone or with both oxidation states concomitantly, respectively. SbIII accumulation was similar in promastigotes and amastigotes of both WT and mutant L. donovani Ld1S.20. The change in SbV accumulation in mutant amastigotes resembles that of WT amastigotes although to a lesser extent, with SbV accumulation increasing by only 4.9-fold.
To determine the intracellular fate of antimony in both promastigotes and amastigotes, cell extracts of parasites treated with SbV, SbIII, or both, were analyzed for each of the antimony oxidation states using FI-HG-ICP-MS. The SbV concentrations used were those that in competition experiments (Figs. 2 and 3) resulted in 10 and 100% inhibition of SbIII toxicity by SbV.
In WT promastigotes incubated with either SbIII or SbV alone, only the specific oxidation state added to the extracellular medium was found intracellularly (Table 1, [SbIII]i and [SbV]i). Most of the accumulated SbV (76%) was identified as intracellular SbV, but only 52% of the accumulated SbIII was recovered by FI-HG-ICP-MS as SbIII. When the extracellular medium contained SbIII and SbV, both these forms were found intracellularly as well with similar SbIII concentrations. SbV accumulated at a 71% higher concentration when parasites were incubated with SbV and SbIII (versus with SbV alone). Similar results were obtained when these experiments were performed using mutant L. donovani Ld1S.20 promastigotes.
In contrast to the above findings, when amastigotes of WT parasites were subjected to the same conditions (Table 2), both SbV and SbIII were detected intracellularly when parasites were incubated with only SbV. Thus, reduction of SbV to SbIII was observed in WT amastigotes incubated with SbV only. When incubated for 12 h with 0.2 mg of SbV/ml, WT amastigotes reduced 29% of the accumulated antimony to SbIII; 18% was reduced when incubation was with 1 mg of SbV/ml. This may indicate that the latter concentration is at saturation for enzymatic SbV reduction. In contrast, only minor levels of reduction of SbV to SbIII in mutant amastigotes occurred. Furthermore, the high level of SbIII accumulation by the mutant amastigotes (Table 2) rules out a possible role for active SbIII efflux in Ld1S.20 resistance to pentavalent antimony.
The results in Tables 1 and 2 indicate that SbV is stable. No spontaneous reduction of SbV to SbIII was observed during the 12-h assays. Only 1% reduction was observed after a few weeks (not shown). This is in agreement with previous observations that SbV is stable in aqueous solutions even though the redox potential favors SbIII (29). Hence, it is likely that rapid reduction of SbV requires intracellular catalytic activity of either an enzymatic or nonenzymatic nature.
To further delineate the nature of the intracellular reduction of
SbV, [SbIII]i was determined
after 3-, 6-, and 12-h incubations of both WT and mutant promastigotes
and amastigotes with SbV alone. As shown in Fig.
1, WT amastigotes showed a
time-dependent reduction of SbV whereas mutant
amastigotes exhibited less than 0.025 of the reducing activity.
Promastigotes, both WT and mutants, did not reduce SbV to
any extent.
|
The results in Fig. 1 and Tables 1 and 2 indicate that SbV reducing activity correlates with the previously documented stage-specific susceptibility of WT amastigotes to pentavalent antimony(12). However, in amastigotes, the intracellular concentration of SbV was 5-fold higher than in promastigotes, suggesting that it may also be toxic to amastigotes. To assess the specific role of SbV in the anti L. donovani activity of antimony, the intracellular relationship between SbV and SbIII was studied with competition assays.
Dose response analyses were performed by incubating wild-type L. donovani 1SR with variable concentrations of sodium stibogluconate (SbV) and a fixed potassium antimonyl tartrate
(SbIII) concentration equivalent to the LD90
for WT L. donovani promastigotes (100 µg/ml = 34 µg
of SbIII/ml). As shown in Fig.
2A, [SbV]
of 200 µg/ml neutralized the toxicity of SbIII,
resulting in no mortality at 1 mg/ml SbV. Also, the minimal
SbV concentration required for reversion of
SbIII toxicity declined with decreasing SbIII
concentration (not shown). A similar relationship between
SbV and SbIII was also shown with promastigotes
from the Pentostam-resistant mutant L. donovani Ld1S.20
(Fig. 2B).
|
In contrast, SbV failed to reverse arsenite (AsIII) toxicity to L. donovani even at SbV concentrations as high as 5 mg/ml (Fig. 2, A and B). These data emphasize the specificity of the SbV-SbIII interaction in L. donovani promastigotes, both WT and mutant.
For wild-type amastigotes, the dose-response curve for SbV
in the presence of a fixed low dose of SbIII (3.4 µg of
SbIII/ml, equivalent to the LD20) showed
additive toxicity of SbV and SbIII (Fig.
3A). In the presence of 34 µg of SbIII/ml (equivalent to the LD90) no
inhibition of SbIII toxicity by SbV was
observed. This is in agreement with the previously reported stage-specific susceptibility of L. donovani to
SbV (12).
|
When the same dose-response analysis was performed using amastigotes of
the L. donovani mutant Ld1S.20, SbV inhibited
SbIII toxicity in a fashion similar to that observed in
promastigotes. As shown in Fig. 3B, [SbV] 200 µg/ml reduced mortality caused by high dose SbIII (34 µg/ml SbIII), and at about 1 mg of SbV/ml no
mortality was observed. When these mutant amastigotes were treated with
AsIII instead of SbIII, SbV failed
to reverse AsIII toxicity, further emphasizing the
specificity of the SbV-SbIII competition.
Differences in antimony intracellular accumulation and reducing activity were observed between promastigotes and amastigotes and between WT and mutant parasites. Furthermore, often total [Sb]i was greater than [SbV + SbIII]i (Tables 1 and 2). Therefore, to ascertain whether antimony metabolism other than oxidation or reduction occurs intracellularly, cell extracts from the above experiments were subjected to anion exchange chromatography, and fractions eluted from the column were directly subjected to ICP-MS.
When a parasite-free solution containing both sodium stibogluconate and
potassium antimonyl tartrate was subjected to HPLC anion exchange
chromatography, two distinct peaks (SbV and
SbIII), were identified. SbV and
SbIII retention times were 100 and 300 s, respectively
(not shown). Fig. 4 shows chromatograms
of WT and mutant amastigotes and promastigotes incubated with
SbV. As shown, when amastigotes were incubated with
SbV, the SbIII peak was absent in the mutant
but not in WT. This correlates with the lack of SbV
reducing activity observed in the mutant amastigotes (Fig. 1). In both
WT and mutant amastigotes, peaks other than free SbV and
SbIII were detected. Differences in peaks A through F were
apparent between WT and mutant. These peaks might represent covalent
interactions of either SbV or SbIII with
intracellular molecules.
|
No major differences were observed between WT and mutant promastigotes
when incubations were performed with SbV (Fig. 4,
C and D). Despite the qualitative nature of the
chromatographic results, the size of both the promastigote
SbIII peaks (WT and mutant) was smaller than in WT
amastigotes, further emphasizing the low level of SbV
reducing activity in promastigotes (Fig. 1).
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Bacteria and yeast that live in environments contaminated with arsenate (AsV) reduce the element intracellularly to arsenite (AsIII) as part of the mechanism that was evolved to evade the toxic effects of this heavy metal (30). Given that Leishmania spp. are not necessarily exposed to heavy metals in their natural habitats (sandflies and vertebrates), they may not have developed this type of protective mechanism. In fact, by reducing nontoxic SbV Leishmania, they actually expose themselves to the lethal effects of SbIII. This work aimed to assess the role of SbV reduction in antimony toxicity to and resistance in L. donovani.
The data presented herein show the following. 1) Intracellular stage-specific SbV reduction occurs in WT L. donovani 1SR and susceptibility to SbV correlates with the level of SbV reducing activity. 2) The SbV-resistant mutant amastigote of L. donovani Ld1S.20 is deficient in SbV intracellular reducing activity. 3) Antimony metabolism with stage-specific differences occurs in both promastigotes and amastigotes of WT L. donovani 1SR and 4) stage-specific intracellular competition between SbIII and SbV, but not AsIII, occurs in WT L. donovani 1SR. This competition is not related to antimony transport.
The results of the experiments described indicate that SbV reverses the toxicity of SbIII to L. donovani promastigotes, in both the WT and the mutant L. donovani Ld1S.20. In addition, SbV and SbIII are toxic in an additive fashion to WT amastigotes. These data support previous findings that described the stage-specific toxicity of SbV, but not of SbIII, to L. donovani (12). In contrast, in mutant L. donovani Ld1S.20 amastigotes, a response similar to promastigotes was observed (inhibition).
In both wild-type and mutant promastigotes and amastigotes, no cross-inhibition by SbV occurs when AsIII is substituted for SbIII. This suggests that, despite similar activity in other biological systems (30, 31), in L. donovani, antimony and arsenic may not act via similar mechanisms.
FI-HG-ICP-MS and FI-ICP-MS data show that both antimony oxidation states, either individually or together, enter promastigotes and axenic amastigotes. The specific quantitative results for combined SbIII and SbV incubation rule out the possibility that competition occurs at the plasma membrane transport level. This is true for both promastigotes and amastigotes of both WT and mutant L. donovani Ld1S.20 parasites.
Because SbV-SbIII antagonism does not take place at the transport level, the assumption that it transpires intracellularly has been borne out. Stage-specific intracellular L. donovani SbV reducing activity exists in WT amastigotes, which reduces negligibly toxic SbV to highly toxic SbIII. In WT promastigotes, the putative L. donovani stage-specific antimony reducing activity may be expressed at either a low level or may be of very low activity, thus explaining the negligible susceptibility of these promastigotes to SbV.
In the mutant L. donovani Ld1S.20 amastigote SbV reducing activity is present either in small amounts or may be nonexistent; thus SbV accumulates intracellularly but is not reduced to SbIII. Consequently mutant amastigotes are less susceptible than WT to SbV. The data presented in Fig. 1 indicate that in WT amastigotes, stage-specific SbV reducing activity occurs, whereas in the mutant amastigote, SbV reduction is less than 0.025 that of WT, thus SbV accumulates intracellularly but is not reduced to SbIII. Furthermore, the observation that both WT and mutant promastigotes and amastigotes accumulate SbIII to the same level (Tables 1 and 2) rules out a possible role for antimonite efflux as the reason for low level of SbIII reduction as well as for Ld1S.20 SbV resistance. The SbV reducing activity of L. donovani might resemble that of the arsenate reductase previously described in bacteria and yeast, which catalyzes reduction of AsV to AsIII (30, 32, 33). It is possible that an L. donovani enzyme that catalyzes SbV reduction plays a key role in parasite susceptibility to antimony. This possibility is currently being investigated in our laboratory.
In WT amastigotes, despite SbV reduction, [SbV]i remains relatively high and theoretically should have inhibited the intracellular SbIII present (Table 2), as seen in both WT and mutant promastigotes as well as in mutant amastigotes. However, the data presented in Fig. 3A show that this does not occur. This might suggest that SbV is directly toxic to WT amastigotes. If this is the case, it must be assumed that SbV toxicity is coupled with SbV reducing activity.
Fig. 5 illustrates a model describing
antimoniate reduction and the subsequent neutralization of
SbIII by trypanothione. We propose that SbIII
accumulates in cells by transport across the plasma membrane and/or by
the intracellular reduction of SbV to SbIII via
either an enzymatic or nonenzymatic mechanism. SbIII then
complexes with trypanothione, and this complex is then extruded from
the parasite via specific transporters, as has been previously proposed
(20, 34, 35). A mutation in a purported stage-specific SbV
reductase would result in resistance of amastigotes to SbV
but not to SbIII. However, any mutation that occurs in
enzymes involved in reactions downstream of the site of the proposed
SbV stage-specific reducing activity should result in
antimony as well as in arsenite-antimony cross-resistance. This could
explain why others have reported
SbV-SbIII-AsIII cross-resistance in
various Leishmania species (11, 20, 22, 36). Furthermore,
the additional role of macrophage-associated antimony reduction in
natural infection, as previously suggested (11, 16, 17), cannot be
ruled out.
|
In promastigotes, the observation that SbV inhibits SbIII toxicity is surprising. No similar phenomenon has been reported before. The intracellular SbV antagonism of SbIII toxicity in WT and mutant promastigotes as well as in mutant amastigotes could occur because of a number of possibilities. In solution, gluconic acid dissociates from antimony and is replaced by hydroxyl groups forming hexahydroxyl antimony, whereas tartrate remains conjugated to SbIII. Thus, SbV antagonism of SbIII is more likely to be a result of noncompetitive inhibition rather than of competitive inhibition (because of structural similarity). Alternatively, an inactive oxide hybrid is formed between potassium antimonyl tartrate and one-half of the sodium stibogluconate molecule. Because SbV is rapidly reduced to SbIII in amastigotes, such hybrids will probably not form. These possibilities are currently being investigated.
The recently developed antimony anion exchange chromatography method (28) showed that SbV is not only reduced but also metabolized by L. donovani. Peaks separated from cell extracts after SbV treatment (Fig. 4) suggest the possibility of covalent interactions of either SbV or SbIII with intracellular molecules. The bound antimony may not be reduced by BH4 (27), thus explaining the differences between total [Sb]i and the reducible intracellular SbV and SbIII measured in Tables 1 and 2.
The amount of antimony accumulated in L. donovani promastigotes and amastigotes are 20 and 300 times higher than that reported for L. panamensis (17). Furthermore, although this New World Leishmania species also exhibits stage-specific susceptibility to SbV, both developmental stages accumulate it to the same extent. Hence, it is likely that in New and Old World species, SbV acts via different modes of action.
The novel approaches of FI-HG-ICP-MS, FI-ICP-MS, and anion exchange
chromatography facilitated the description of intracellular antimony
metabolism in L. donovani promastigotes and amastigotes, both WT and mutant. To the best of our knowledge, this is the first
description of intracellular SbV reduction in parasitic
protozoa as well as in any intact cell.
![]() |
ACKNOWLEDGEMENTS |
---|
We thank Prof. Stephen M. Beverley and Dr. Mark L. Cunningham for useful discussions.
![]() |
FOOTNOTES |
---|
* This work was supported by Grant 3668 from the Chief Scientist, Ministry of Health, Jerusalem, Israel, and by Grant T24-86-1 from the UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
To whom correspondence should be addressed. E-mail:
danz@tx.technion.ac.il.
Published, JBC Papers in Press, November 11, 2000, DOI 10.1074/jbc.M005423200
![]() |
ABBREVIATIONS |
---|
The abbreviations used are: FI-ICP-MS, flow injection-inductively coupled plasma mass-spectrometry; FI-HG-ICP-MS, flow injection-hydride generation-inductively coupled plasma-mass spectrometry; IC-ICP-MS, ion-chromatography-inductively coupled plasma-mass-spectrometry; WT, wild type; HPLC, high performance liquid chromatography; LD, lethal dose.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1. | Herwaldt, B. L. (1999) Lancet 364, 1191-1199[CrossRef] |
2. | Chang, K. P., and Dwyer, D. M. (1976) Science 193, 678-680[Medline] [Order article via Infotrieve] |
3. | Handman, E. (1999) Adv. Parasitol. 44, 1-39[Medline] [Order article via Infotrieve] |
4. | Joshi, M., Dwyer, D. M., and Nakhasi, H. L. (1993) Mol. Biochem. Parasitol. 58, 345-354[CrossRef][Medline] [Order article via Infotrieve] |
5. | Saar, Y., Asamoa, R., Waldman, E., Mazareb, S., Amin-Spector, S., Plumblee, J., Turco, S. J., and Zilberstein, D. (1998) Mol. Biochem. Parasitol. 95, 9-20[CrossRef][Medline] [Order article via Infotrieve] |
6. | Chattopadhayay, R., Kaur, S., Ganguly, N. K., and Mahajan, R. C. (1996) Ind. J. Med. Res. 104, 349-354[Medline] [Order article via Infotrieve] |
7. | Basselin, M., Lawrence, F., and Robert-Gero, M. (1996) Biochem. J. 315, 631-634[Medline] [Order article via Infotrieve] |
8. | Mazareb, S., Fu, Z. Y., and Zilberstein, D. (1999) Exp. Parasitol. 91, 341-348[CrossRef][Medline] [Order article via Infotrieve] |
9. | Mengeling, B. J., Zilberstein, D., and Turco, S. J. (1997) Glycobiology 7, 847-853[Abstract] |
10. | Amin-Spector, S., and Zilberstein, D. (2001) Parasitol. Today, in press |
11. |
Sereno, D.,
Cavaleyra, M.,
Zemzoumi, K.,
Maquaire, S.,
Ouaissi, A.,
and Lemesre, J. L.
(1998)
Antimicrob. Agents Chemother.
42,
3097-3102 |
12. |
Ephros, M.,
Bitnun, A.,
Shaked, P.,
Waldman, E.,
and Zilberstein, D.
(1999)
Antimicrob. Agents Chemother.
43,
278-282 |
13. | Ephros, M., Waldman, E., and Zilberstein, D. (1997) Antimicrob. Agents Chemother. 41, 1064-1068[Abstract] |
14. | Goodwin, L. G. (1995) Trans. R. Soc. Trop. Med. Hyg. 89, 339-341[Medline] [Order article via Infotrieve] |
15. | Goodwin, L. G., and Page, J. E. (1943) Biochem. J. 22, 236-240 |
16. | Berman, J. D., Waddell, D., and Hanson, B. D. (1985) Antimicrob. Agents Chemother. 27, 916-920[Medline] [Order article via Infotrieve] |
17. | Roberts, W. L., Berman, J. D., and Rainey, P. M. (1995) Antimicrob. Agents Chemother. 39, 1234-1239[Abstract] |
18. | Roberts, W. L., and Rainey, P. M. (1993) Antimicrob. Agents Chemother. 37, 1842-1846[Abstract] |
19. | Callahan, H. L., Portal, A. C., Devereaux, R., and Grogl, M. (1997) Antimicrob. Agents Chemother. 41, 818-822[Abstract] |
20. |
Haimeur, A.,
and Ouellette, M.
(1998)
Antimicrob. Agents Chemother.
42,
1689-1694 |
21. | Dey, S., Papadopoulou, B., Roy, G., Grondin, K., Dou, D., Rosen, B. P., Ouellette, M., and Haimeur, A. (1994) Mol. Biochem. Parasitol. 67, 49-57[CrossRef][Medline] [Order article via Infotrieve] |
22. | Borst, P., and Ouellette, M. (1995) Annu. Rev. Microbiol. 49, 427-460[CrossRef][Medline] [Order article via Infotrieve] |
23. |
Roberts, W. L.,
McMurray, W. J.,
and Rainey, P. M.
(1998)
Antimicrob. Agents Chemother.
42,
1076-1082 |
24. | Dwyer, D. M. (1977) Exp. Parasitol. 41, 341-358[Medline] [Order article via Infotrieve] |
25. | Ulrich, N. (1998) Anal. Chim. Acta 359, 245-253[CrossRef] |
26. | Ulrich, N. (1998) Fresenius J. Anal. Chem. 360, 797-800[CrossRef] |
27. | Ulrich, N. (2000) Anal. Chim. Acta 417, 201-209[CrossRef] |
28. | Ulrich, N., Shaked-Mishan, P., and Zilberstein, D. (2000) Fresenius J. Anal. Chem. 368, 62-66[CrossRef][Medline] [Order article via Infotrieve] |
29. | Lugo de Yarbuh, A., Anez, N., Petit de Pena, Y., Burguera, J. L., and Burguera, M. (1994) Annu. Trop. Med. Parasitol. 88, 37-41 |
30. | Rosen, B. P. (1999) Trends Microbiol. 7, 207-212[CrossRef][Medline] [Order article via Infotrieve] |
31. | Rosen, B. P. (1995) J. Basic Clin. Physiol. Pharmacol. 6, 251-263[Medline] [Order article via Infotrieve] |
32. | Mukhopadhyay, R., and Rosen, B. P. (1998) FEMS Microbiol. Lett. 168, 127-136[CrossRef][Medline] [Order article via Infotrieve] |
33. |
Liu, J.,
and Rosen, B. P.
(1997)
J. Biol. Chem.
272,
21084-21089 |
34. |
Dey, S.,
Ouellette, M.,
Lightbody, J.,
Papadopoulou, B.,
and Rosen, B. P.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
2192-2197 |
35. | Ouellette, M., Legare, D., Haimeur, A., Grondin, K., Ray, G., Brochu, C., and Papadopoulou, B. (1998) Drug Resistance Updates 1, 43-48 |
36. |
Grondin, K.,
Haimeur, A.,
Mukhopadhyay, R.,
Rosen, B. P.,
and Ouellette, M.
(1997)
EMBO J.
16,
3057-3065 |